Stock Futures Waver on Weak Global Data

August crude oil futures were down 88 cents at $80.57 a barrel. August gold futures were off $16.90 to $1,598.90 an ounce.

The benchmark 10-year Treasury was up 5/32, diluting the yield to 1.645%, while the dollar was trading sideways, according to the dollar index.

In corporate news, Rite Aid(RAD) reported first-quarter earnings Thursday that met analysts' expectations but it lowered its sales guidance for the year.

The drugstore chain reported a first-quarter loss of $30.7 million, or 3 cents a share, narrower than a year-earlier loss of $65.5 million, or 7 cents a share.

Analysts, on average, were expecting a loss of 3 cents a share.

Rite Aid lowered its fiscal 2013 sales guidance to between $25.3 billion and $25.7 billion and said it expects same-store sales to decline between 0.5% and 1%. The company previously anticipated sales would be between $25.4 billion and $25.8 billion with same-store sales between flat and an increase of 1.5%.

Red Hat (RHT) beat Wall Street's first-quarter profit expectations but it posted weak billings and provided second-quarter guidance slightly below estimates.

Billings, defined as revenue plus the change in deferred revenue, came in at $310 million. Wall Street was expecting $319 million, according to Mizuho Securities analyst Abhey Lamba, who has a buy rating on the stock.

Bed Bath & Beyond (BBBY) , the specialty retailer, gave a disappointing outlook on Wednesday for its fiscal second quarter.

The company said it expects earnings of 97 cents to $1.03 a share in the three months ending in August, below analysts' expectations of a profit of $1.08 a share.

Johnson & Johnson(JNJ) and the Justice Department are close to settling an investigation into the company's alleged improper promotion of the antipsychotic Risperdal, The Wall Street Journal reported, citing people familiar with the matter.

The two sides are discussing a payment of at least $1.5 billion, some of the people told the newspaper.

The settlement would be one of the highest sums to date in a drug-marketing case, the Journal said.